Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696607 | 0.89 | SLC6A2 (0.75) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL4407320 | 0.89 | SLC6A2 (0.75) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL3118256 | 0.85 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL7062835 | 0.81 | DRD4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL8449011 | 0.79 | DRD4 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL507357 | 0.77 | DRD4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL3130245 | 0.77 | DRD4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL18792538 | 0.77 | NAAA (0.50) | SLC6A4SLC6A2SLC6A3KCNH2DRD4 | |
| SCHEMBL19281802 | 0.77 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL17460169 | 0.77 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | SLC6A4 4238/4885SLC6A2 4604/4885SLC6A3 4617/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | SLC6A4 4257/4885SLC6A2 4545/4885SLC6A3 4624/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | SLC6A4 4238/4885SLC6A2 4604/4885SLC6A3 4617/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | SLC6A4 4381/4885SLC6A2 4632/4885SLC6A3 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.